Venom and Toxin as Targeted Therapy
Targeted therapy has developed significantly in the last one and half decades, prescribing specific medications for treatment of particular diseases, such as cancer, diabetes, and heart disease. One of the most exciting recent developments in targeted therapies was the isolation of disease-specific...
Сохранить в:
| Главный автор: | |
|---|---|
| Формат: | Online |
| Язык: | английский |
| Опубликовано: |
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
| Предметы: | |
| Online-ссылка: | 42564 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|
| _version_ | 1869519479584587776 |
|---|---|
| author | Kwok, Hang Fai (Henry) |
| author_browse | Kwok, Hang Fai (Henry) |
| author_facet | Kwok, Hang Fai (Henry) |
| author_sort | Kwok, Hang Fai (Henry) |
| collection | Directory of Open Access Books |
| description | Targeted therapy has developed significantly in the last one and half decades, prescribing specific medications for treatment of particular diseases, such as cancer, diabetes, and heart disease. One of the most exciting recent developments in targeted therapies was the isolation of disease-specific molecules from natural resources, such as animal venoms and plant metabolites/toxins, for use as templates for new drug motif designs. In addition, the study of venom proteins/peptides and toxins naturally targeted mammalian receptors and demonstrated high specificity and selectivity towards defined ion channels of cell membranes. Research has also focsed intensely on receptors. The focus of this Special Issue of Toxins addressed the most recent advances using animal venoms, such as frog secretions, bee/ant venoms and plant/fungi toxins, as medicinal therapy. Recent advances in venom/toxin/immunotoxins for targeted cancer therapy and immunotherapy, along with using novel disease-specific venom-based protein/peptide/toxin and currently available FDA-approved drugs for combinationtreatments will be discussed. Finally, we included an overview of select promising toad/snake venom-based peptides/toxins potentially able to address the forthcoming challenges in this field. Both research and review articles proposing novelties or overviews, respectively, were published in this Special Issue after rigorous evaluation and revision by expert peer reviewers. |
| format | Online |
| id | doab-20.500.12854ir-61900 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-619002024-04-05T12:32:21Z Venom and Toxin as Targeted Therapy Kwok, Hang Fai (Henry) QH301-705.5 Q1-390 cane toad n/a B cell non-Hodgkin lymphoma Malaysian cobras complement system decay accelerating factor neuroblastoma atopic dermatitis complement dependent cytotoxicity antioxidant enzymes bacterial adhesion cancer therapy N. kaouthia anuran skin secretion frog Apis mellifera syriaca solid phase extraction bee venom phospholipase A2 (bvPLA2) disintegrin toad toxins immunotoxins ribosome-inactivating proteins antimicrobial peptide (AMP) drug design Moxetumomab pasudotox snake venom antiviral activity in vitro effects bombesin-related peptide oxidative stress biomarkers half-life blood vessel formation target therapy 2 MYCN indolealkylamines Huachansu membrane attack complex bouganin bee venom SEM anticancer activity antimicrobial peptide house dust mite extract (DFE) mannose receptor O. hannah bicarinalin gastric cells melittin LC-ESI-MS dermaseptin smooth muscle apoptosis anticancer N. sumatrana Helicobacter pylori inflammation immunotherapy atopic dermatitis (AD) immunotoxin mantle cell lymphoma clearance mass spectrometry Bougainvillea rRNA N-glycosylase activity fungal toxin skin inflammation targeted therapy 4-dinitrochlorobenzene (DNCB) Bee venom VEGF Chansu bufadienolides obsessive–compulsive disorder (OCD) BLF1 antimicrobial activity orellanine VB6-845 acute lymphoblastic leukemia ribosome-inactivating protein CD206 molecular cloning cancer CD22 eIF4A thema EDItEUR::P Mathematics and Science::PS Biology, life sciences Targeted therapy has developed significantly in the last one and half decades, prescribing specific medications for treatment of particular diseases, such as cancer, diabetes, and heart disease. One of the most exciting recent developments in targeted therapies was the isolation of disease-specific molecules from natural resources, such as animal venoms and plant metabolites/toxins, for use as templates for new drug motif designs. In addition, the study of venom proteins/peptides and toxins naturally targeted mammalian receptors and demonstrated high specificity and selectivity towards defined ion channels of cell membranes. Research has also focsed intensely on receptors. The focus of this Special Issue of Toxins addressed the most recent advances using animal venoms, such as frog secretions, bee/ant venoms and plant/fungi toxins, as medicinal therapy. Recent advances in venom/toxin/immunotoxins for targeted cancer therapy and immunotherapy, along with using novel disease-specific venom-based protein/peptide/toxin and currently available FDA-approved drugs for combinationtreatments will be discussed. Finally, we included an overview of select promising toad/snake venom-based peptides/toxins potentially able to address the forthcoming challenges in this field. Both research and review articles proposing novelties or overviews, respectively, were published in this Special Issue after rigorous evaluation and revision by expert peer reviewers. 2021-02-12T07:25:46Z 2021-02-12T07:25:46Z 2019-12-09 11:49:15 2019 book 42564 9783039211890 9783039211906 https://directory.doabooks.org/handle/20.500.12854/61900 eng application/octet-stream Attribution-NonCommercial-NoDerivatives 4.0 International https://mdpi.com/books/pdfview/book/1648 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-03921-190-6 10.3390/books978-3-03921-190-6 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783039211890 9783039211906 180 open access |
| spellingShingle | QH301-705.5 Q1-390 cane toad n/a B cell non-Hodgkin lymphoma Malaysian cobras complement system decay accelerating factor neuroblastoma atopic dermatitis complement dependent cytotoxicity antioxidant enzymes bacterial adhesion cancer therapy N. kaouthia anuran skin secretion frog Apis mellifera syriaca solid phase extraction bee venom phospholipase A2 (bvPLA2) disintegrin toad toxins immunotoxins ribosome-inactivating proteins antimicrobial peptide (AMP) drug design Moxetumomab pasudotox snake venom antiviral activity in vitro effects bombesin-related peptide oxidative stress biomarkers half-life blood vessel formation target therapy 2 MYCN indolealkylamines Huachansu membrane attack complex bouganin bee venom SEM anticancer activity antimicrobial peptide house dust mite extract (DFE) mannose receptor O. hannah bicarinalin gastric cells melittin LC-ESI-MS dermaseptin smooth muscle apoptosis anticancer N. sumatrana Helicobacter pylori inflammation immunotherapy atopic dermatitis (AD) immunotoxin mantle cell lymphoma clearance mass spectrometry Bougainvillea rRNA N-glycosylase activity fungal toxin skin inflammation targeted therapy 4-dinitrochlorobenzene (DNCB) Bee venom VEGF Chansu bufadienolides obsessive–compulsive disorder (OCD) BLF1 antimicrobial activity orellanine VB6-845 acute lymphoblastic leukemia ribosome-inactivating protein CD206 molecular cloning cancer CD22 eIF4A thema EDItEUR::P Mathematics and Science::PS Biology, life sciences Kwok, Hang Fai (Henry) Venom and Toxin as Targeted Therapy |
| title | Venom and Toxin as Targeted Therapy |
| title_full | Venom and Toxin as Targeted Therapy |
| title_fullStr | Venom and Toxin as Targeted Therapy |
| title_full_unstemmed | Venom and Toxin as Targeted Therapy |
| title_short | Venom and Toxin as Targeted Therapy |
| title_sort | venom and toxin as targeted therapy |
| topic | QH301-705.5 Q1-390 cane toad n/a B cell non-Hodgkin lymphoma Malaysian cobras complement system decay accelerating factor neuroblastoma atopic dermatitis complement dependent cytotoxicity antioxidant enzymes bacterial adhesion cancer therapy N. kaouthia anuran skin secretion frog Apis mellifera syriaca solid phase extraction bee venom phospholipase A2 (bvPLA2) disintegrin toad toxins immunotoxins ribosome-inactivating proteins antimicrobial peptide (AMP) drug design Moxetumomab pasudotox snake venom antiviral activity in vitro effects bombesin-related peptide oxidative stress biomarkers half-life blood vessel formation target therapy 2 MYCN indolealkylamines Huachansu membrane attack complex bouganin bee venom SEM anticancer activity antimicrobial peptide house dust mite extract (DFE) mannose receptor O. hannah bicarinalin gastric cells melittin LC-ESI-MS dermaseptin smooth muscle apoptosis anticancer N. sumatrana Helicobacter pylori inflammation immunotherapy atopic dermatitis (AD) immunotoxin mantle cell lymphoma clearance mass spectrometry Bougainvillea rRNA N-glycosylase activity fungal toxin skin inflammation targeted therapy 4-dinitrochlorobenzene (DNCB) Bee venom VEGF Chansu bufadienolides obsessive–compulsive disorder (OCD) BLF1 antimicrobial activity orellanine VB6-845 acute lymphoblastic leukemia ribosome-inactivating protein CD206 molecular cloning cancer CD22 eIF4A thema EDItEUR::P Mathematics and Science::PS Biology, life sciences |
| topic_facet | QH301-705.5 Q1-390 cane toad n/a B cell non-Hodgkin lymphoma Malaysian cobras complement system decay accelerating factor neuroblastoma atopic dermatitis complement dependent cytotoxicity antioxidant enzymes bacterial adhesion cancer therapy N. kaouthia anuran skin secretion frog Apis mellifera syriaca solid phase extraction bee venom phospholipase A2 (bvPLA2) disintegrin toad toxins immunotoxins ribosome-inactivating proteins antimicrobial peptide (AMP) drug design Moxetumomab pasudotox snake venom antiviral activity in vitro effects bombesin-related peptide oxidative stress biomarkers half-life blood vessel formation target therapy 2 MYCN indolealkylamines Huachansu membrane attack complex bouganin bee venom SEM anticancer activity antimicrobial peptide house dust mite extract (DFE) mannose receptor O. hannah bicarinalin gastric cells melittin LC-ESI-MS dermaseptin smooth muscle apoptosis anticancer N. sumatrana Helicobacter pylori inflammation immunotherapy atopic dermatitis (AD) immunotoxin mantle cell lymphoma clearance mass spectrometry Bougainvillea rRNA N-glycosylase activity fungal toxin skin inflammation targeted therapy 4-dinitrochlorobenzene (DNCB) Bee venom VEGF Chansu bufadienolides obsessive–compulsive disorder (OCD) BLF1 antimicrobial activity orellanine VB6-845 acute lymphoblastic leukemia ribosome-inactivating protein CD206 molecular cloning cancer CD22 eIF4A thema EDItEUR::P Mathematics and Science::PS Biology, life sciences |
| url | 42564 |
| work_keys_str_mv | AT kwokhangfaihenry venomandtoxinastargetedtherapy |